Jan Bolinder

Jan Bolinder

Auto-generated profile, based on publicly available information

Jan Bolinder

Department of Medicine, Karolinska University Hospital Huddinge, Karolinska Institute, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in The Lancet
Verified
Journal Article
Closed access
JBJan Bolinder
Jan Bolinder
RARamiro Antuna
Ramiro Antuna
PGPetronella Geelhoed-Duijvestijn
Petronella Geelhoed-Duijvestijn
JKJens Kröger
Jens Kröger
RWRaimund Weitgasser
Raimund Weitgasser

1 March 2012 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
JBJan Bolinder
Jan Bolinder
ÖLÖsten Ljunggren
Östen Ljunggren
JKJoel Kullberg
Joel Kullberg
LJLars Johansson
Lars Johansson
JWJohn Wilding
John Wilding
SPShamik Parikh
Shamik Parikh
Dapagliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduces hyperglycemia in patients with type 2 diabetes mellitus (T2DM) by increasing urinary glucose excretion, and weight loss is a consistent associated finding. Our objectives were to confirm weight loss with dapagliflozin and establish through body composition measurements whether weight loss is accounted for by changes in fat or fluid components. This was a 24-wk, international, multicenter, randomized, parallel-group, double-blind, placebo-controlled study with ongoing 78-wk site- and patient-blinded extension period at 40 sites in five countries. Included were 182 patients with T2DM (mean values: women 63.3 and men 58.6 yr of age; hemoglobin A1c 7.17%, body mass index 31.9 kg/m2, and body weight 91.5 kg) inadequately controlled on metformin. Dapagliflozin 10 mg/d or placebo was added to open-label metformin for 24 wk. Primary endpoint was total body weight (TBW) change from baseline at wk 24. Key secondary endpoints were waist circumference and dual-energy x-ray absorptiometry total-body fat mass (FM) changes from baseline at wk 24, and patient proportion achieving body weight reduction of at least 5% at wk 24. In a subset of patients, magnetic resonance assessment of visceral adipose tissue (VAT) and sc adipose tissue (SAT) volume and hepatic lipid content were also evaluated. At wk 24, placebo-corrected changes with dapagliflozin were as follows: TBW, -2.08 kg [95% confidence interval (CI)=-2.84 to -1.31; P<0.0001]; waist circumference, -1.52 cm (95% CI=-2.74 to -0.31; P=0.0143); FM, -1.48 kg (95% CI=-2.22 to -0.74; P=0.0001); proportion of patients achieving weight reduction of at least 5%, +26.2% (95% CI=15.5 to 36.7; P<0.0001); VAT, -258.4 cm3 (95% CI=-448.1 to -68.6; nominal P=0.0084); SAT, -184.9 cm3 (95% CI=-359.7 to -10.1; nominal P=0.0385). In the dapagliflozin vs. placebo groups, respectively, serious adverse events were reported in 6.6 vs. 1.1%; events suggestive of vulvovaginitis, balanitis, and related genital infection in 3.3 vs. 0%; and lower urinary tract infections in 6.6 vs. 2.2%. Dapagliflozin reduces TBW, predominantly by reducing FM, VAT and SAT in T2DM inadequately controlled with metformin.

24 January 2017 in JAMA
Verified
Journal Article
Open access
PDF file
MLMarcus Lind
Marcus Lind
WPWilliam Polonsky
William Polonsky
IHIrl B. Hirsch
Irl B. Hirsch
THTim Heise
Tim Heise
JBJan Bolinder
Jan Bolinder
JHJarl Hellman
Jarl Hellman
Intensive insulin therapy resulting in good glycemic control has been shown to prevent and reduce the progression of diabetes-related complications in patients with type 1 diabetes.1 Today, intensive glycemic control is generally achieved through multiple daily insulin injections or continuous subcutaneous insulin infusions through an insulin pump.2 Regular self-measured capillary blood glucose values have been crucial to optimal insulin dosing for good glycemic control.3- 5

1 December 2006 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
DDDorothee Deiss
Dorothee Deiss
JBJan Bolinder
Jan Bolinder
JRJean-Pierre Riveline
Jean-Pierre Riveline
TBTadej Battelino
Tadej Battelino
EBEmanuele Bosi
Emanuele Bosi
MPMoshe Phillip
Moshe Phillip
Intensive self-management with frequent self-monitoring of blood glucose (SMBG) is important in type 1 diabetes to achieve good metabolic control (1–3). Nevertheless, many patients still experience episodes of unrecognized hypo- and hyperglycemia (4). Novel technologies for continuous glucose monitoring (CGM) that provide information about glucose excursions are now available. Previous studies reported the benefits of retrospective evaluation of CGM data (5–11), but few assessed effects on glycemic control (5,12–14), and only one showed improvements compared with SMBG (14). We evaluated the effect of a new real-time glucose monitor on glycemic control in patients with poorly controlled type 1 diabetes. The device, Guardian RT (Medtronic MiniMed, Northridge, CA), allows users to see glucose readings and set hypo- and hyperglycemic alarms and provides trend information on changing glucose values. The study included 81 children (median age 14.4 years [range 8.0–18.9]) and 81 adults (age 39.1 years [19.0–59.5]) with stable type 1 diabetes. All had adhered to intensified insulin treatment (continuous subcutaneous insulin infusion, n = 78; multiple daily injection, n = 84) but had HbA1c (A1C) levels ≥8.1%. Informed consent was obtained from patients regularly attending the eight participating centers. Subjects were randomly assigned 1:1:1 for 3 months to Guardian RT continuously (arm 1) or biweekly for 3-day periods every 2 weeks (arm 2) or to continue conventional SMBG (control). Treatment adjustments made by physicians and patients were based on SMBG profiles in control subjects and on real-time glucose profiles in arms 1 and 2. Patients were instructed to perform confirmatory SMBG measurements before therapeutical interventions or corrective action if hypo- or hyperglycemic alarms or symptoms occurred. …

1 August 2013 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
JBJ. Bolinder
J. Bolinder
ÖLÖ. Ljunggren
Ö. Ljunggren
LJL. Johansson
L. Johansson
JWJohn Wilding
John Wilding
ALA. M. Langkilde
A. M. Langkilde
SPS. Parikh
S. Parikh
Aims: Dapagliflozin, a highly selective inhibitor of sodium‐glucose cotransporter 2 ( SGLT2 ), reduces hyperglycaemia and weight in patients with type 2 diabetes mellitus ( T2DM ) by increasing urinary glucose excretion. Long‐term glycaemic control, body composition and bone safety were evaluated in patients with T2DM after 102 weeks of dapagliflozin treatment. Methods: This randomized, double‐blind, placebo‐controlled study ( NCT00855166 ) enrolled patients with T2DM [mean: age 60.7 years; HbA1c 7.2%; body mass index ( BMI ) 31.9 kg/m 2 ; body weight 91.5 kg] inadequately controlled on metformin. Patients (N = 182) were randomly assigned 1 : 1 to receive dapagliflozin 10 mg/day or placebo added to open‐label metformin for a 24‐week double‐blind treatment period followed by a 78‐week site‐ and patient‐blinded extension period. At week 102, changes from baseline in HbA1c , weight, waist circumference, total body fat mass as measured by dual‐energy X‐ray absorptiometry ( DXA ), serum markers of bone turnover, bone mineral density ( BMD ) as measured by DXA , and adverse events were evaluated. Results: A total of 140 patients (76.9%) completed the study. Over 102 weeks, dapagliflozin‐treated patients showed reductions in HbA1c by −0.3%, weight by −4.54 kg, waist circumference by −5.0 cm and fat mass by −2.80 kg without increase in rate of hypoglycaemia. Compared with placebo, no meaningful changes from baseline in markers of bone turnover or BMD were identified over 102 weeks. One fracture occurred in each treatment group. The frequency of urinary tract infection ( UTI ) and genital infection was similar in both treatment groups. Conclusions: Over 102 weeks, dapagliflozin improved glycaemic control, and reduced weight and fat mass, without affecting markers of bone turnover or BMD in patients with T2DM inadequately controlled on metformin.

11 September 2012 in Diabetologia
Verified
Journal Article
Open access
PDF file
TGthe SWITCH Study Group
the SWITCH Study Group
TBTadej Battelino
Tadej Battelino
ICI. Conget
I. Conget
BOB. Olsen
B. Olsen
ISI. Schütz-Fuhrmann
I. Schütz-Fuhrmann
JBJ. Bolinder
J. Bolinder
Aims/hypothesis The aim of this multicentre, randomised, controlled crossover study was to determine the efficacy of adding continuous glucose monitoring (CGM) to insulin pump therapy (CSII) in type 1 diabetes. Methods Children and adults (n = 153) on CSII with HbA1c 7.5–9.5% (58.5–80.3 mmol/mol) were randomised to (CGM) a Sensor On or Sensor Off arm for 6 months. After 4 months’ washout, participants crossed over to the other arm for 6 months. Paediatric and adult participants were separately electronically randomised through the case report form according to a predefined randomisation sequence in eight secondary and tertiary centres. The primary outcome was the difference in HbA1c levels between arms after 6 months. Results Seventy-seven participants were randomised to the On/Off sequence and 76 to the Off/On sequence; all were included in the primary analysis. The mean difference in HbA1c was –0.43% (–4.74 mmol/mol) in favour of the Sensor On arm (8.04% [64.34 mmol/mol] vs 8.47% [69.08 mmol/mol]; 95% CI −0.32%, −0.55% [−3.50, −6.01 mmol/mol]; p < 0.001). Following cessation of glucose sensing, HbA1c reverted to baseline levels. Less time was spent with sensor glucose <3.9 mmol/l during the Sensor On arm than in the Sensor Off arm (19 vs 31 min/day; p = 0.009). The mean number of daily boluses increased in the Sensor On arm (6.8 ± 2.5 vs 5.8 ± 1.9, p < 0.0001), together with the frequency of use of the temporary basal rate (0.75 ± 1.11 vs 0.26 ± 0.47, p < 0.0001) and manual insulin suspend (0.91 ± 1.25 vs 0.70 ± 0.75, p < 0.018) functions. Four vs two events of severe hypoglycaemia occurred in the Sensor On and Sensor Off arm, respectively (p = 0.40). Conclusions/interpretation Continuous glucose monitoring was associated with decreased HbA1c levels and time spent in hypoglycaemia in individuals with type 1 diabetes using CSII. More frequent self-adjustments of insulin therapy may have contributed to these effects. Trial registration ClinicalTrials.gov registration no. NCT00598663. Funding The study was funded by Medtronic International Trading Sarl Switzerland.